A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of a Single Dose of Donzakimig in Healthy Chinese and Japanese Participants
Completed · Phase 1 · NCT06716879
Conditions: Healthy Participants
At a glance
- Research payments reported, 2025
- $934,495
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 32
About the trial
- Sponsor
- UCB Biopharma SRL
- Tested
- Donzakimig (drug), Placebo (drug)
- Dates
- Started 2024-12-06; completion 2025-04-04
- Results posted
- Not yet
The purpose of the study is to investigate the safety, tolerability, and pharmacokinetic parameters of 2 dose strengths of donzakimig, each administered subcutaneously as a single dose, in healthy Chinese and Japanese study participants.
From ClinicalTrials.gov, last updated 2026-02-18. Full record, eligibility and contacts (opens in a new tab)
Industry funding
UCB SA reported $934,495 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Anaheim Clinical Trials LLC $934,495
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.